Patents by Inventor Timothy L. Bullock

Timothy L. Bullock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HAPLOID INDUCTION COMPOSITIONS AND METHODS FOR USE THEREFOR
    Publication number: 20240099213
    Abstract: Provided here are methods of using a mutated patatin-like phospholipase II? (“pPLAII?,” renamed here MATRILINEAL) to induce haploid induction in plants, cloning a pPLAII? to induce haploid induction in plants, and genetically engineering a plant to contain a mutated pPLAII?. Also provided are methods of applying topical and spray chemicals, lipids, and RNAi molecules to plants during pollination in order to induce haploid production. Further provided are methods of chemically treating plants during pollination to induce haploids while also reducing embryo abortion and increasing seed set.
    Type: Application
    Filed: November 30, 2023
    Publication date: March 28, 2024
    Applicant: Syngenta Participations AG
    Inventors: Timothy Kelliher, Satya Chintamanani, Brent Delzer, Michael L Nuccio, Robert Arthur Dietrich, Suresh Babu Kadaru, Todd Lee Warner, William Paul Bullock
  • SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM
    Publication number: 20140010885
    Abstract: A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
    Type: Application
    Filed: January 18, 2012
    Publication date: January 9, 2014
    Inventors: Miguel de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
  • CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME
    Publication number: 20110293726
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosed chimeric therapeutics.
    Type: Application
    Filed: April 8, 2011
    Publication date: December 1, 2011
    Inventors: Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
  • CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME
    Publication number: 20110293725
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
    Type: Application
    Filed: April 8, 2011
    Publication date: December 1, 2011
    Inventors: Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
  • CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME
    Publication number: 20110293727
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.
    Type: Application
    Filed: April 8, 2011
    Publication date: December 1, 2011
    Inventors: Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
  • Compositions and methods for treating B-cell malignancies
    Patent number: 8067011
    Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 29, 2011
    Assignee: Chimeros, Inc.
    Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
  • Self-assembling nanoparticle drug delivery system
    Publication number: 20090226525
    Abstract: A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
    Type: Application
    Filed: April 9, 2008
    Publication date: September 10, 2009
    Inventors: Miguel de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski